Latest Healthcare Research Reports

Tag: primary biliary cholangitis market forecast

Primary Biliary Cholangitis Market Projected To Surpass $1.59 Billion By 2030 At 8.7% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Primary Biliary Cholangitis Market Between 2026 And 2030?

The market size for primary biliary cholangitis has experienced substantial growth in recent years. Projections indicate it will expand from $1.06 billion in 2025 to $1.15 billion in 2026, driven by a compound annual growth rate (CAGR) of 8.4%. The increase observed in previous periods is attributable to an improved understanding of autoimmune liver diseases, greater availability of diagnostic testing, the expansion of specialty liver clinics, rising clinical awareness of pbc symptoms, and the advancement of standard pharmacological treatments.

The primary biliary cholangitis market is anticipated to show robust expansion in the upcoming years. It is projected to climb to $1.6 billion by 2030, progressing at a compound annual growth rate (CAGR) of 8.7%. This expected growth within the forecast period can be attributed to factors such as increased investment in rare disease research, a rising adoption of personalized medicine approaches, the broadening scope of advanced imaging diagnostics, an expanding pipeline of targeted therapies, and a greater emphasis on early-stage disease management. Notable trends for the forecast timeframe include an intensified focus on targeted drug therapies, the increasing use of advanced diagnostic imaging techniques, the growing integration of biomarker-based disease monitoring, the expansion of personalized treatment strategies, and an enhanced emphasis on early disease detection.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

Which Core Factors Are Supporting The Expansion Of The Primary Biliary Cholangitis Market?

The increasing incidence of liver cancer is anticipated to boost the expansion of the primary biliary cholangitis market in the future. Liver cancer refers to a malignancy that originates in the cells of the liver. primary biliary cholangitis plays a crucial role in liver cancer development, largely because it elevates the risk of different malignancies such as cholangiocarcinoma and hepatocellular carcinoma. The rising occurrence of the condition and its associated complications further contribute to the expansion of the primary biliary cholangitis market. For example, in January 2024, the American Cancer Society, a prominent professional body in the U.S., estimated around 41,630 new diagnoses of liver cancer nationally, comprising 28,000 cases in men and 13,630 in women. Moreover, approximately 29,840 individuals (19,120 men and 10,720 women) are predicted to die from this illness. Consequently, the rise in liver cancer is propelling the growth of the primary biliary cholangitis market.

How Is Segment Classification Applied In The Primary Biliary Cholangitis Market?

The primary biliary cholangitis market covered in this report is segmented –

1) By Treatment Type: Drugs, Liver Transplantation

2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

3) By End-Users: Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

What Trends Are Influencing The Future Of The Primary Biliary Cholangitis Market?

Leading companies in the primary antibody market are concentrating on developing innovative products, such as mutation-specific antibodies, with the goal of improving diagnostic accuracy, enhancing workflow efficiency, and mitigating misdiagnosis risks. A mutation-specific antibody functions as a reagent engineered to bind selectively to a defined antigen variant rather than a broad native antigen population, thereby enabling clinicians to target specific protein mutations with high precision. For instance, in February 2023, F. Hoffmann-La Roche AG, a Switzerland-based diagnostics and pharmaceutical company, launched the IDH1 R132H (MRQ 67) rabbit monoclonal primary antibody and the ATRX rabbit polyclonal antibody. These offerings provide high specificity for the IDH1 R132H mutation, are compatible with the BenchMark IHC/ISH platform, and facilitate automated workflows for neuropathology. While these antibodies boost diagnostic precision and workflow efficiency, they also incur higher development costs and possess a narrower range of target applicability.

Who Are The Companies Shaping The Primary Biliary Cholangitis Market Landscape?

Major companies operating in the primary biliary cholangitis market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck And Co Inc, Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Dr Reddys Laboratories Ltd, Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Intercept Pharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc, Albireo Pharma Inc, Genfit SA, CymaBay Therapeutics Inc, Ascletis Pharma Inc, Ipsen Pharma, Ferring Pharmaceuticals

Access The Complete Primary Biliary Cholangitis Market Report:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

What Is The Largest Regional Market In The Primary Biliary Cholangitis Market?

North America was the largest region in the primary biliary cholangitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Primary Biliary Cholangitis Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Market 2026, By The Business Research Company

Polyclonal Antibodies Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Diagnostic Specialty Antibodies Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/diagnostic-specialty-antibodies-global-market-report

Next Generation Antibody Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

June 3, 2026
Primary Biliary Cholangitis Market Developments and Opportunities Through 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Primary Biliary Cholangitis Market Between 2026 And 2030?

The market size for primary biliary cholangitis has shown substantial growth in recent years. It is anticipated to expand from $1.06 billion in 2025 to $1.15 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.4%. This historical growth can be largely attributed to an improved understanding of autoimmune liver diseases, an increase in the availability of diagnostic testing, the expansion of specialty liver clinics, a rising clinical awareness of PBC symptoms, and the development of standard pharmacological treatments.

The market size for primary biliary cholangitis is anticipated to experience robust expansion over the next few years, projected to reach $1.6 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. This growth during the forecast period is attributable to heightened investments in rare disease research, an increasing uptake of personalized medicine strategies, the expansion of advanced imaging diagnostic tools, a growing pipeline of targeted therapies, and a stronger focus on managing the disease in its early stages. Furthermore, significant trends expected in this period include a greater emphasis on targeted drug therapies, the rising adoption of sophisticated diagnostic imaging techniques, the increasing integration of biomarker-based disease monitoring, the broadening of personalized treatment approaches, and an enhanced focus on early disease detection.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

Which Key Factors Are Driving The Primary Biliary Cholangitis Market Growth?

An increase in liver cancer is anticipated to boost the expansion of the primary biliary cholangitis market. Liver cancer, which originates in the liver’s cells, is a form of malignancy. Primary biliary cholangitis plays a crucial role in the context of liver cancer, as it significantly raises the likelihood of developing various cancers, including cholangiocarcinoma and hepatocellular carcinoma. The increasing occurrence of the disease and its potential complications further contribute to the expansion of the primary biliary cholangitis market. For example, in January 2024, the American Cancer Society, a prominent professional body in the U.S., forecasted about 41,630 new liver cancer diagnoses nationwide, comprising 28,000 cases among men and 13,630 among women. Additionally, approximately 29,840 individuals (19,120 men and 10,720 women) are anticipated to die from this illness. Consequently, the rising incidence of liver cancer is a key factor propelling the expansion of the primary biliary cholangitis market.

How Is Segmentation Applied In The Primary Biliary Cholangitis Market Segment Analysis?

The primary biliary cholangitis market covered in this report is segmented –

1) By Treatment Type: Drugs, Liver Transplantation

2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

3) By End-Users: Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

Which Trends Are Guiding The Direction Of The Primary Biliary Cholangitis Market?

Leading companies in the primary biliary cholangitis market are focusing on developing innovative and specialized treatments, such as orphan drugs that combine obeticholic acid (OCA) and bezafibrates to address primary biliary cholangitis (PBC), in order to secure market exclusivity. This specific combination of OCA and bezafibrate, with its orphan drug designation, is designed to present a more comprehensive and effective strategy for managing PBC treatment, potentially elevating the quality of life for individuals afflicted by this uncommon condition. For example, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, was granted orphan drug designation from the FDA for the combination of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, for its potential use as a treatment for primary biliary cholangitis (PBC), which is a progressive liver disease. Furthermore, obeticholic acid (marketed as Ocaliva) is already approved for PBC in the US.

Who Are The Companies Participating In The Primary Biliary Cholangitis Market Environment?

Major companies operating in the primary biliary cholangitis market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck And Co Inc, Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Dr Reddys Laboratories Ltd, Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Intercept Pharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc, Albireo Pharma Inc, Genfit SA, CymaBay Therapeutics Inc, Ascletis Pharma Inc, Ipsen Pharma, Ferring Pharmaceuticals

Get The Full Primary Biliary Cholangitis Market Report:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

Which Region Leads The Primary Biliary Cholangitis Market In Terms Of Market Share?

North America was the largest region in the primary biliary cholangitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Primary Biliary Cholangitis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Market 2026, By The Business Research Company

Polyclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Diagnostic Specialty Antibodies Market Report

https://www.thebusinessresearchcompany.com/report/diagnostic-specialty-antibodies-global-market-report

Next Generation Antibody Therapeutics Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

April 27, 2026
One of the Major Drivers of the Primary Biliary Cholangitis Market Is the Surge In Liver Cancer Cases Fuels Growth In Primary Biliary Cholangitis Market

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Primary Biliary Cholangitis Market During The Forecast Period 2026–2030?

The market for primary biliary cholangitis has experienced robust expansion in recent years. This market is projected to expand from $1.06 billion in 2025 to $1.15 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 8.4%. Historical growth in this sector is largely due to factors such as a deeper comprehension of autoimmune liver conditions, enhanced access to diagnostic evaluations, the proliferation of specialized liver clinics, increasing clinical recognition of pbc symptoms, and the establishment of conventional pharmacological therapies.

The market size for primary biliary cholangitis is projected to exhibit robust growth over the coming years, reaching $1.6 billion by 2030 at a compound annual growth rate (CAGR) of 8.7%. This expansion during the forecast period is driven by factors such as increasing investments in rare disease research, the rising embrace of personalized medicine strategies, the growth of advanced imaging diagnostics, an expanding pipeline of targeted therapies, and a greater emphasis on early-stage disease management. Notable trends for the forecast period include a heightened focus on targeted drug therapies, the growing adoption of sophisticated diagnostic imaging techniques, an increasing integration of biomarker-based disease monitoring, the broadening of personalized treatment approaches, and an enhanced commitment to early disease detection.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

Which Major Factors Are Driving The Expansion Of The Primary Biliary Cholangitis Market?

The increasing incidence of liver cancer is projected to stimulate the expansion of the primary biliary cholangitis market. Liver cancer is defined as a form of cancer that originates within the liver’s cells. The importance of primary biliary cholangitis in relation to liver cancer is considerable, stemming from its heightened risk for various malignancies, including cholangiocarcinoma and hepatocellular carcinoma. The expanding prevalence of this condition and its potential health issues contribute to the development of the primary biliary cholangitis market. As an illustration, in January 2024, the American Cancer Society, a major professional group in the U.S., forecast roughly 41,630 new diagnoses of liver cancer across the country, with 28,000 cases affecting men and 13,630 women. Moreover, around 29,840 people (19,120 men and 10,720 women) are anticipated to die from this disease. Thus, the escalation in liver cancer acts as a key driver for the primary biliary cholangitis market’s growth.

What Market Segments Are Evaluated Within The Primary Biliary Cholangitis Market?

The primary biliary cholangitis market covered in this report is segmented –

1) By Treatment Type: Drugs, Liver Transplantation

2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

3) By End-Users: Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

What Trends Are Projected To Affect The Primary Biliary Cholangitis Market?

Leading companies within the primary biliary cholangitis market are concentrating on creating novel and specialized therapeutic options, including orphan drugs that combine obeticholic acid (OCA) and bezafibrates for the treatment of primary biliary cholangitis (PBC), seeking to secure exclusive market positions. This combination of OCA and bezafibrate, having received an orphan drug designation, is intended to provide a more holistic and impactful method for handling PBC treatment, with the potential to enhance the quality of life for those living with this uncommon illness. An illustrative example is Intercept Pharmaceuticals, Inc., a a US-based biopharmaceutical firm, which obtained orphan drug designation from the FDA in May 2023 for its combination therapy of obeticholic acid (OCA) and bezafibrate, identified as a PPAR agonist, as a prospective therapy for primary biliary cholangitis (PBC), which is a progressive liver condition; notably, obeticholic acid itself (known commercially as Ocaliva) is already approved for PBC in the US.

Who Are The Top Market Participants Influencing The Primary Biliary Cholangitis Market?

Major companies operating in the primary biliary cholangitis market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck And Co Inc, Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Dr Reddys Laboratories Ltd, Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Intercept Pharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc, Albireo Pharma Inc, Genfit SA, CymaBay Therapeutics Inc, Ascletis Pharma Inc, Ipsen Pharma, Ferring Pharmaceuticals

Read the full primary biliary cholangitis market report here:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

Which Region Currently Holds The Largest Share Of The Primary Biliary Cholangitis Market?

North America was the largest region in the primary biliary cholangitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Primary Biliary Cholangitis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Market 2026, By The Business Research Company

Polyclonal Antibodies Global Market Report

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Diagnostic Specialty Antibodies Global Market Report

https://www.thebusinessresearchcompany.com/report/diagnostic-specialty-antibodies-global-market-report

Next Generation Antibody Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

April 6, 2026
Primary Biliary Cholangitis Market 2026–2030: Emerging Trends and Forecast Opportunities

Uncover key drivers, emerging technologies, and competitive movements shaping the primary biliary cholangitis market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Primary Biliary Cholangitis Market show for the 2026–2030 period?

The primary biliary cholangitis market has experienced substantial expansion in recent years. Projections indicate it will increase from $1.06 billion in 2025 to $1.15 billion in 2026, with a compound annual growth rate (CAGR) of 8.4%. This historical growth is attributable to an enhanced understanding of autoimmune liver diseases, greater availability of diagnostic testing, the proliferation of specialty liver clinics, heightened clinical awareness of pbc symptoms, and the evolution of standard pharmacological treatments.

The primary biliary cholangitis market is anticipated to show significant expansion in the upcoming years, reaching $1.6 billion by 2030 with a compound annual growth rate (CAGR) of 8.7%. This expansion in the projected timeframe is largely due to increased funding for rare disease research, the growing acceptance of personalized medicine approaches, the broader availability of advanced imaging diagnostics, an expanding array of targeted therapies in development, and a heightened emphasis on managing the disease in its initial stages. Notable trends for the forecast period include a greater concentration on targeted drug therapies, increased usage of advanced diagnostic imaging techniques, the rising integration of biomarker-based disease monitoring, the proliferation of personalized treatment options, and an enhanced focus on early disease detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

What Drivers Are Shaping The Development Of The Primary Biliary Cholangitis Market?

An anticipated rise in liver cancer cases is projected to drive the expansion of the primary biliary cholangitis market moving ahead. Liver cancer is identified as a malignancy originating within the liver’s cells. The connection between primary biliary cholangitis and liver cancer holds substantial importance, stemming from the elevated risk of diverse cancers like cholangiocarcinoma and hepatocellular carcinoma. The increasing incidence of this disease and its associated complications further fuel the growth of the primary biliary cholangitis market. To illustrate, in January 2024, the American Cancer Society, a prominent professional body in the U.S., forecast around 41,630 new diagnoses of liver cancer nationwide, comprising 28,000 cases among men and 13,630 among women. Furthermore, an estimated 29,840 individuals (19,120 men and 10,720 women) are anticipated to die from this illness. Consequently, the escalation in liver cancer incidence is propelling the expansion of the primary biliary cholangitis market.

Which Segments Are Contributing To The Growth Of The Primary Biliary Cholangitis Market?

The primary biliary cholangitis market covered in this report is segmented –

1) By Treatment Type: Drugs, Liver Transplantation

2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

3) By End-Users: Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

Which Trends Are Influencing The Performance And Direction Of The Primary Biliary Cholangitis Market?

Leading companies in the primary biliary cholangitis market are concentrating on developing innovative and specialized treatments, such as orphan drugs involving a combination of obeticholic acid (OCA) and bezafibrates to address primary biliary cholangitis (PBC), with the goal of achieving market exclusivity. This specific combination of OCA and bezafibrate, supported by an orphan drug designation, aims to provide a more thorough and effective approach to managing PBC treatment, potentially enhancing the quality of life for individuals living with this rare condition. For example, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, obtained orphan drug designation from the FDA for the combination of obeticholic acid (OCA) and bezafibrate, identified as a PPAR agonist, as a potential treatment for primary biliary cholangitis (PBC), a progressive liver disease; furthermore, obeticholic acid (marketed as Ocaliva) is already approved for PBC in the US.

Who Are The Core Companies Influencing Trends In The Primary Biliary Cholangitis Market?

Major companies operating in the primary biliary cholangitis market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck And Co Inc, Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Dr Reddys Laboratories Ltd, Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Intercept Pharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc, Albireo Pharma Inc, Genfit SA, CymaBay Therapeutics Inc, Ascletis Pharma Inc, Ipsen Pharma, Ferring Pharmaceuticals

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

Which Regions Are Projected To Dominate The Primary Biliary Cholangitis Market In The Coming Years?

North America was the largest region in the primary biliary cholangitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Primary Biliary Cholangitis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Market 2026, By The Business Research Company

Hepatic Encephalopathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatic-encephalopathy-global-market-report

Diverticulitis Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Bilirubin Blood Test Market Report 2026

https://www.thebusinessresearchcompany.com/report/bilirubin-blood-test-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

March 2, 2026
Primary Biliary Cholangitis Market 2026–2030: Emerging Trends and Forecast Opportunities

Uncover key drivers, emerging technologies, and competitive movements shaping the primary biliary cholangitis market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Primary Biliary Cholangitis Market show for the 2026–2030 period?

The primary biliary cholangitis market has experienced substantial expansion in recent years. Projections indicate it will increase from $1.06 billion in 2025 to $1.15 billion in 2026, with a compound annual growth rate (CAGR) of 8.4%. This historical growth is attributable to an enhanced understanding of autoimmune liver diseases, greater availability of diagnostic testing, the proliferation of specialty liver clinics, heightened clinical awareness of pbc symptoms, and the evolution of standard pharmacological treatments.

The primary biliary cholangitis market is anticipated to show significant expansion in the upcoming years, reaching $1.6 billion by 2030 with a compound annual growth rate (CAGR) of 8.7%. This expansion in the projected timeframe is largely due to increased funding for rare disease research, the growing acceptance of personalized medicine approaches, the broader availability of advanced imaging diagnostics, an expanding array of targeted therapies in development, and a heightened emphasis on managing the disease in its initial stages. Notable trends for the forecast period include a greater concentration on targeted drug therapies, increased usage of advanced diagnostic imaging techniques, the rising integration of biomarker-based disease monitoring, the proliferation of personalized treatment options, and an enhanced focus on early disease detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

What Drivers Are Shaping The Development Of The Primary Biliary Cholangitis Market?

An anticipated rise in liver cancer cases is projected to drive the expansion of the primary biliary cholangitis market moving ahead. Liver cancer is identified as a malignancy originating within the liver’s cells. The connection between primary biliary cholangitis and liver cancer holds substantial importance, stemming from the elevated risk of diverse cancers like cholangiocarcinoma and hepatocellular carcinoma. The increasing incidence of this disease and its associated complications further fuel the growth of the primary biliary cholangitis market. To illustrate, in January 2024, the American Cancer Society, a prominent professional body in the U.S., forecast around 41,630 new diagnoses of liver cancer nationwide, comprising 28,000 cases among men and 13,630 among women. Furthermore, an estimated 29,840 individuals (19,120 men and 10,720 women) are anticipated to die from this illness. Consequently, the escalation in liver cancer incidence is propelling the expansion of the primary biliary cholangitis market.

Which Segments Are Contributing To The Growth Of The Primary Biliary Cholangitis Market?

The primary biliary cholangitis market covered in this report is segmented –

1) By Treatment Type: Drugs, Liver Transplantation

2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

3) By End-Users: Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

Which Trends Are Influencing The Performance And Direction Of The Primary Biliary Cholangitis Market?

Leading companies in the primary biliary cholangitis market are concentrating on developing innovative and specialized treatments, such as orphan drugs involving a combination of obeticholic acid (OCA) and bezafibrates to address primary biliary cholangitis (PBC), with the goal of achieving market exclusivity. This specific combination of OCA and bezafibrate, supported by an orphan drug designation, aims to provide a more thorough and effective approach to managing PBC treatment, potentially enhancing the quality of life for individuals living with this rare condition. For example, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, obtained orphan drug designation from the FDA for the combination of obeticholic acid (OCA) and bezafibrate, identified as a PPAR agonist, as a potential treatment for primary biliary cholangitis (PBC), a progressive liver disease; furthermore, obeticholic acid (marketed as Ocaliva) is already approved for PBC in the US.

Who Are The Core Companies Influencing Trends In The Primary Biliary Cholangitis Market?

Major companies operating in the primary biliary cholangitis market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck And Co Inc, Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Dr Reddys Laboratories Ltd, Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Intercept Pharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc, Albireo Pharma Inc, Genfit SA, CymaBay Therapeutics Inc, Ascletis Pharma Inc, Ipsen Pharma, Ferring Pharmaceuticals

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

Which Regions Are Projected To Dominate The Primary Biliary Cholangitis Market In The Coming Years?

North America was the largest region in the primary biliary cholangitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Primary Biliary Cholangitis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Market 2026, By The Business Research Company

Hepatic Encephalopathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatic-encephalopathy-global-market-report

Diverticulitis Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Bilirubin Blood Test Market Report 2026

https://www.thebusinessresearchcompany.com/report/bilirubin-blood-test-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

March 2, 2026
Primary Biliary Cholangitis Market 2026–2030: Emerging Trends and Forecast Opportunities

Uncover key drivers, emerging technologies, and competitive movements shaping the primary biliary cholangitis market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Primary Biliary Cholangitis Market show for the 2026–2030 period?

The primary biliary cholangitis market has experienced substantial expansion in recent years. Projections indicate it will increase from $1.06 billion in 2025 to $1.15 billion in 2026, with a compound annual growth rate (CAGR) of 8.4%. This historical growth is attributable to an enhanced understanding of autoimmune liver diseases, greater availability of diagnostic testing, the proliferation of specialty liver clinics, heightened clinical awareness of pbc symptoms, and the evolution of standard pharmacological treatments.

The primary biliary cholangitis market is anticipated to show significant expansion in the upcoming years, reaching $1.6 billion by 2030 with a compound annual growth rate (CAGR) of 8.7%. This expansion in the projected timeframe is largely due to increased funding for rare disease research, the growing acceptance of personalized medicine approaches, the broader availability of advanced imaging diagnostics, an expanding array of targeted therapies in development, and a heightened emphasis on managing the disease in its initial stages. Notable trends for the forecast period include a greater concentration on targeted drug therapies, increased usage of advanced diagnostic imaging techniques, the rising integration of biomarker-based disease monitoring, the proliferation of personalized treatment options, and an enhanced focus on early disease detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

What Drivers Are Shaping The Development Of The Primary Biliary Cholangitis Market?

An anticipated rise in liver cancer cases is projected to drive the expansion of the primary biliary cholangitis market moving ahead. Liver cancer is identified as a malignancy originating within the liver’s cells. The connection between primary biliary cholangitis and liver cancer holds substantial importance, stemming from the elevated risk of diverse cancers like cholangiocarcinoma and hepatocellular carcinoma. The increasing incidence of this disease and its associated complications further fuel the growth of the primary biliary cholangitis market. To illustrate, in January 2024, the American Cancer Society, a prominent professional body in the U.S., forecast around 41,630 new diagnoses of liver cancer nationwide, comprising 28,000 cases among men and 13,630 among women. Furthermore, an estimated 29,840 individuals (19,120 men and 10,720 women) are anticipated to die from this illness. Consequently, the escalation in liver cancer incidence is propelling the expansion of the primary biliary cholangitis market.

Which Segments Are Contributing To The Growth Of The Primary Biliary Cholangitis Market?

The primary biliary cholangitis market covered in this report is segmented –

1) By Treatment Type: Drugs, Liver Transplantation

2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

3) By End-Users: Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

Which Trends Are Influencing The Performance And Direction Of The Primary Biliary Cholangitis Market?

Leading companies in the primary biliary cholangitis market are concentrating on developing innovative and specialized treatments, such as orphan drugs involving a combination of obeticholic acid (OCA) and bezafibrates to address primary biliary cholangitis (PBC), with the goal of achieving market exclusivity. This specific combination of OCA and bezafibrate, supported by an orphan drug designation, aims to provide a more thorough and effective approach to managing PBC treatment, potentially enhancing the quality of life for individuals living with this rare condition. For example, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, obtained orphan drug designation from the FDA for the combination of obeticholic acid (OCA) and bezafibrate, identified as a PPAR agonist, as a potential treatment for primary biliary cholangitis (PBC), a progressive liver disease; furthermore, obeticholic acid (marketed as Ocaliva) is already approved for PBC in the US.

Who Are The Core Companies Influencing Trends In The Primary Biliary Cholangitis Market?

Major companies operating in the primary biliary cholangitis market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck And Co Inc, Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Dr Reddys Laboratories Ltd, Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Intercept Pharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc, Albireo Pharma Inc, Genfit SA, CymaBay Therapeutics Inc, Ascletis Pharma Inc, Ipsen Pharma, Ferring Pharmaceuticals

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

Which Regions Are Projected To Dominate The Primary Biliary Cholangitis Market In The Coming Years?

North America was the largest region in the primary biliary cholangitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Primary Biliary Cholangitis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Market 2026, By The Business Research Company

Hepatic Encephalopathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/hepatic-encephalopathy-global-market-report

Diverticulitis Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report

Bilirubin Blood Test Market Report 2026

https://www.thebusinessresearchcompany.com/report/bilirubin-blood-test-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

March 2, 2026
Global Primary Biliary Cholangitis Market Growth Prospects and Strategic Opportunities Through 2029

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Is The Primary Biliary Cholangitis Market Expected To Grow In Terms Of Size?

The market size for primary biliary cholangitis has seen robust growth in the past few years. An expansion from $0.98 billion in 2024 to an estimated $1.06 billion in 2025 is expected, with a compound annual growth rate (CAGR) of 7.9%. Factors contributing to this rise during the historical period include heightened awareness about the disease, increment in global healthcare spending, strategic partnerships within the healthcare sector, emphasis on patient advocacy, and government health initiatives aimed at liver health.

Expected to witness significant growth in the coming years, the market size for primary biliary cholangitis is projected to reach $1.47 billion in 2029 with a compound annual growth rate (CAGR) of 8.6%. Factors contributing to growth during the forecast period include the advancement in biomarker research, worldwide efforts to manage rare diseases, increased collaboration in clinical trials, focus on patient-centered healthcare, and a rising demand for liver transplants. The forecast period will also see trends such as progress in biomarker research, a growing emphasis on non-invasive diagnostic methods, a research focus on immunomodulatory treatments, the incorporation of artificial intelligence (AI), patient-reported results in clinical trials, the use of telemedicine for patient management, a focus on combination treatments, as well as the emergence of therapies targeting fibrosis.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

Which Key Factors Are Fueling Growth In The Primary Biliary Cholangitis Market?

The upward trend in smoking is anticipated to boost the expansion of the primary biliary cholangitis market in the future. The term smoking denotes the process of inhaling and exhaling smoke from burned tobacco or other materials. It’s well-known that smoking is a significant risk factor for liver diseases, such as PBC, meaning higher smoking rates can result in a greater number of people seeking treatment for liver-related conditions. For example, in July 2023, as per Statistics Canada, a governmental agency from Canada, there was a 2.2% increase in cigarette production as compared to June 2023 in the country. There was also a 2.6% boost in cigarette sales in June, with sales hitting 1.4 billion units compared to May. Therefore, the surging smoking incidences will contribute to the growth of the primary biliary cholangitis market.

How Is The Primary Biliary Cholangitis Market Categorized Across Applications And Types?

The primary biliary cholangitismarket covered in this report is segmented –

1) By Treatment Type: Drugs; Liver Transplantation

2) By Diagnosis: Imaging Tests; Magnetic Resonance Elastography (MRE); Magnetic Resonance Cholangiopancreatography (MRCP); Ultrasound; Fibroscan; Blood Tests; Cholesterol Test; Antibody Tests; Liver Tests; Other Diagnoses

3) By End-Users: Specialty Clinics; Homecare; Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA); Obeticholic Acid (OCA); Fibrates; Immunosuppressive Drugs; Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT); Living Donor Liver Transplantation; Hepatobiliary Surgery For Liver Transplant

How Are Industry Trends Steering The Expansion Of The Primary Biliary Cholangitis Market?

Primary biliary cholangitis market players are concentrating their efforts on the creation of unique and effective treatments for the condition, like orphan drugs that are a blend of obeticholic acid (OCA) and bezafibrates, aiming for market monopoly. The union of OCA and bezafibrate is intended to provide a more holistically efficient solution to primary biliary cholangitis management, potentially enhancing the lives of those impacted by this uncommon ailment. For example, in May 2023, Intercept Pharmaceuticals, Inc., a biopharmaceutical company based in the US, was granted orphan drug status by the FDA for a potential PBC treatment combo of OCA and a PPAR agonist, bezafibrate, with obeticholic acid (marketed under the name Ocaliva) having been approved for PBC treatment in the US.

Which Firms Are Making The Biggest Impact In The Primary Biliary Cholangitis Market?

Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

Which Region Holds The Greatest Opportunity For Primary Biliary Cholangitis Market Expansion?

North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Market 2025, By The Business Research Company

Gastroesophageal Reflux Disease Gerd Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-gerd-global-market-report

Migraine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/migraine-global-market-report

Myelodysplastic Syndrome Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

December 1, 2025
Primary Biliary Cholangitis Industry Anticipated to Expand at 8.6% CAGR During the Forecast Period

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Primary Biliary Cholangitis Market By 2029?

The primary biliary cholangitis market size has experienced strong growth over recent years. It is set to expand from $0.98 billion in 2024 to $1.06 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.9%. The expansion observed during the historic period stems from increased disease awareness, rising global healthcare expenditure, strategic collaborations within the healthcare sector, a focus on patient advocacy, and government initiatives supporting liver health.

The primary biliary cholangitis market size is projected to experience substantial growth in the coming years, reaching $1.47 billion by 2029, at a compound annual growth rate (CAGR) of 8.6%. This anticipated expansion can be attributed to several factors, including the increasing scope of biomarker research, global initiatives in rare disease management, enhanced collaboration in clinical trials, the adoption of patient-centric healthcare approaches, and a rising demand for liver transplants. Throughout the forecast period, significant trends are expected to include further advancements in biomarker research, a greater emphasis on non-invasive diagnostic techniques, dedicated research into immunomodulatory therapies, the integration of artificial intelligence (AI), the inclusion of patient-reported outcomes in clinical trials, the expanding use of telemedicine for patient management, a focus on combination therapies, and the emergence of new treatments specifically targeting fibrosis.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

Which Drivers Are Supporting Growth Of The Primary Biliary Cholangitis Market?

Rising smoking levels are anticipated to propel the growth of the primary biliary cholangitis market going forward. Smoking involves the act of inhaling and exhaling the smoke produced by burning tobacco or other substances. It is a recognized risk factor for liver diseases, including PBC, and higher smoking rates can lead to more individuals seeking medical attention for liver-related issues. For instance, in July 2023, according to Statistics Canada, a Canada-based government agency, cigarette production increased by 2.2% compared to June 2023 in Canada. Moreover, there was a 2.6% rise in cigarette sales in June, reaching 1.4 billion units compared to May. Therefore, the increase in smoking will drive the growth of the primary biliary cholangitis market.

What Are The Emerging Segments Gaining Attention In The Primary Biliary Cholangitis Market?

The primary biliary cholangitismarket covered in this report is segmented –

1) By Treatment Type: Drugs; Liver Transplantation

2) By Diagnosis: Imaging Tests; Magnetic Resonance Elastography (MRE); Magnetic Resonance Cholangiopancreatography (MRCP); Ultrasound; Fibroscan; Blood Tests; Cholesterol Test; Antibody Tests; Liver Tests; Other Diagnoses

3) By End-Users: Specialty Clinics; Homecare; Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA); Obeticholic Acid (OCA); Fibrates; Immunosuppressive Drugs; Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT); Living Donor Liver Transplantation; Hepatobiliary Surgery For Liver Transplant

How Are Trends Influencing The Primary Biliary Cholangitis Market?

Companies active in the primary biliary cholangitis market are prioritizing the development of innovative and specialized treatments, such as orphan drugs featuring a combination of obeticholic acid (OCA) and bezafibrates for primary biliary cholangitis (PBC), with the goal of achieving market exclusivity. This specific combination of OCA and bezafibrate, holding an orphan drug designation, aims to present a more comprehensive and effective strategy for managing PBC treatment, potentially enhancing the quality of life for individuals affected by this rare condition. For instance, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, received orphan drug designation from the FDA for the combination of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, as a potential therapy for primary biliary cholangitis (PBC), a progressive liver disease. It’s also noted that obeticholic acid (marketed as Ocaliva) is approved for PBC in the US.

Who Are The Primary Competitors In The Global Primary Biliary Cholangitis Market?

Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

Which Geographies Are Emerging As Strong Markets For The Primary Biliary Cholangitis Industry?

North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Primary Biliary Cholangitis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

Browse Through More Reports Similar to the Global Primary Biliary Cholangitis Market 2025, By The Business Research Company

Gastroesophageal Reflux Disease Gerd Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-gerd-global-market-report

Migraine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/migraine-global-market-report

Myelodysplastic Syndrome Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

November 25, 2025
Primary Biliary Cholangitis Market Insights: In-Depth Look at Growth Trends, Market Size, and Opportunities for 2025-2034

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Milestones in the Primary Biliary Cholangitis Market’s Growth Trajectory From 2025 To 2034?

The market for primary biliary cholangitis has experienced robust growth in the past few years. Projections reveal an increase from $0.98 billion in 2024 to $1.06 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.9%. This significant increase during the historical period can be credited to heightened disease awareness, escalating global health expenditure, strategic partnerships within the healthcare industry, emphasis on patient advocacy, and government-led efforts aimed at preserving liver health.

The market for primary biliary cholangitis is poised to experience robust growth in the years to come, with expectations for it to reach a worth of $1.47 billion in 2029 and a CAGR of 8.6%. This growth projection during the forecast period can be linked to factors such as the progress in biomarker research, international initiatives dealing with rare diseases, enhanced cooperation in conducting clinical trials, and a shift towards healthcare strategies that prioritize patient needs, along with the increasing need for liver transplants. Anticipated trends during this forecast period involve progress in research related to biomarkers, heightened emphasis on non-invasive methods for diagnostics, concentration on immunomodulatory therapies in research, incorporation of artificial intelligence (AI), the use of patient-reported outcomes during clinical trials, application of telemedicine for patient care, focus on combination therapies, and the development of new treatments targeting fibrosis.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

What External and Internal Drivers Are Contributing to the Growth of thePrimary Biliary Cholangitis Market?

The primary biliary cholangitis market is anticipated to grow, owing to the escalation in smoking. Smoking, characterized by the inhalation and exhalation of smoke from burning tobacco or other substances, is an established risk factor for liver diseases like PBC. The rise in smoking rates could prompt a higher number of individuals to seek healthcare for liver-associated complications. For example, in July 2023, Statistics Canada, a government agency in Canada, reported a 2.2% increase in cigarette production compared to June 2023. Furthermore, cigarette sales saw a 2.6% boost in June, totalling 1.4 billion units, showing a growth compared to the previous month. Hence, the growing incidence of smoking is set to fuel the expansion of the primary biliary cholangitis market.

What Segment Types Define the Primary Biliary Cholangitis Market Structure?

The primary biliary cholangitismarket covered in this report is segmented –

1) By Treatment Type: Drugs; Liver Transplantation

2) By Diagnosis: Imaging Tests; Magnetic Resonance Elastography (MRE); Magnetic Resonance Cholangiopancreatography (MRCP); Ultrasound; Fibroscan; Blood Tests; Cholesterol Test; Antibody Tests; Liver Tests; Other Diagnoses

3) By End-Users: Specialty Clinics; Homecare; Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA); Obeticholic Acid (OCA); Fibrates; Immunosuppressive Drugs; Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT); Living Donor Liver Transplantation; Hepatobiliary Surgery For Liver Transplant

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Primary Biliary Cholangitis Market?

North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Primary Biliary Cholangitis Market?

In the primary biliary cholangitis market, corporate entities are prioritizing the creation of unique and niche treatments, such as orphan drugs mixed with obeticholic acid (OCA) and bezafibrates for primary biliary cholangitis (PBC) handling, to attain exclusive rights to the market. The co-mingling of OCA and bezafibrate with an orphan drug tag intends to provide a more encompassing and effective method for managing PBC therapeutics, which could potentially enhance the livelihood of those suffering from this uncommon condition. For example, In May 2023, Intercept Pharmaceuticals, Inc., a biopharmaceutical firm based in the US, was granted orphan drug designation by the FDA for its blend of obeticholic acid (OCA) and bezafibrate, which function as a PPAR agonist and could potentially treat primary biliary cholangitis (PBC), a disease that gradually worsens the liver. The same market also approved obeticholic acid (sold under the brand name Ocaliva) for PBC use within the US.

View the full report here:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

What Is the Definition of the Primary Biliary Cholangitis Market?

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive inflammation and destruction of the small bile ducts within the liver. This condition can lead to impaired bile flow, liver damage, and various related complications. PBC primarily affects middle-aged women and is often associated with symptoms such as fatigue, itching, and abdominal discomfort.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13520

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

September 15, 2025
Primary Biliary Cholangitis Market Size to Exceed $1.6 Billion by 2029 | Growth and Industry Trends

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Primary Biliary Cholangitis Market Grown from 2024 to 2025?

The market size for primary biliary cholangitis has seen swift expansion in the recent past. An increase from $0.98 billion in 2024 to $1.09 billion in 2025 is anticipated, indicating a compound annual growth rate (CAGR) of 11.8%. The substantial growth in the earlier period is credited to heightened awareness of the disease, escalated healthcare expenditure worldwide, strategic alliances in healthcare segment, emphasis on patient advocacy, along with government commitments towards liver health.

What Growth Rate Is Anticipated for the Primary Biliary Cholangitis Market in the Coming Years?

In the coming years, the market size for primary biliary cholangitis is predicted to exhibit robust expansion, reaching $1.6 billion by 2029, at a compound annual growth rate (CAGR) of 9.9%. The projected growth in the forecast period is largely due to advancements in biomarker studies, international endeavors in managing rare diseases, amplified partnerships in clinical trials and a patient-focused approach in healthcare, along with escalating demand for liver transplants. Significant trends determining the growth during the forecast period encompass progress in biomarker studies, a heightened focus on non-invasive diagnostic procedures, research emphasis on immunomodulatory treatments, the introduction of artificial intelligence (ai), the inclusion of patient-generated outcomes in clinical trials, telemedicine’s role in patient care, concentration on combination treatments, and emerging therapies aimed at fibrosis.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

Who Are the Leading Companies in the Primary Biliary Cholangitis Market?

Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.

What Are the Key Drivers of the Primary Biliary Cholangitis Market?

The rise in smoking rates is predicted to fuel the expansion of the primary biliary cholangitis market. The practice of smoking, characterized by the inhalation and exhalation of smoke from burned tobacco or other substances, is a recognized risk factor for various liver diseases, including PBC. Therefore, an increase in smoking prevalence can lead to a greater number of people seeking treatment for hepatic issues. For example, Statistics Canada documented that cigarette production in Canada enhanced by 2.2% in July 2023 compared to the previous month. Furthermore, the country witnessed a 2.6% surge in cigarette sales in June, touching 1.4 billion units, an increment from May. Thus, the ballooning smoking rates will propel the progress of the primary biliary cholangitis market. As for the primary biliary cholangitis market, a significant driver of its progression is the rise in liver cancer cases. Identified as a cancer type that initiates in liver cells, liver cancer’s relationship with primary biliary cholangitis is considerable due to the heightened risk of different malignancies, such as cholangiocarcinoma and hepatocellular carcinoma. The increasing prevalence of the disease and its probable complications boost the growth of the primary biliary cholangitis market. For instance, the American Cancer Society projected around 41,630 new liver cancer cases in the U.S in January 2024, with 28,000 in men and 13,630 in women. In addition, an estimated 29,840 individuals (19,120 men and 10,720 women) are expected to die from this malady. Hence, this spike in liver cancer cases is accelerating the expansion of the primary biliary cholangitis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

What Are the Key Market Segments in the Primary Biliary Cholangitis Industry?

The primary biliary cholangitis market covered in this report is segmented –

1) By Treatment Type: Drugs, Liver Transplantation

2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

3) By End-Users: Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

What Are the Latest Trends in the Primary Biliary Cholangitis Market?

Businesses in the primary biliary cholangitis market are concentrating their efforts on the creation of advanced and tailored therapies like orphan drugs, which combine obeticholic acid (OCA) and bezafibrates to tackle primary biliary cholangitis (PBC), in order to achieve market exclusivity. The aim of coupling OCA and bezafibrate with orphan drug status is to establish a more complete and efficient strategy for managing PBC treatment, which might enhance the wellbeing of those affected by this uncommon ailment. For instance, in May 2023, the FDA granted orphan drug status to Intercept Pharmaceuticals, Inc., a biopharmaceutical firm based in the US, for the combination of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, as a prospective treatment for primary biliary cholangitis, a progressive liver disease. Meanwhile, obeticholic acid is approved for PBC under the brand name Ocaliva in the US.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

What Are the Key Regional Markets in the Primary Biliary Cholangitis Industry?

North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13520

This Report Delivers Insight On:

1. How big is the primary biliary cholangitis market, and how is it changing globally?

2. Who are the major companies in the primary biliary cholangitis market, and how are they performing?

3. What are the key opportunities and risks in the primary biliary cholangitis market right now?

4. Which products or customer segments are growing the most in the primary biliary cholangitis market?

5. What factors are helping or slowing down the growth of the primary biliary cholangitis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

July 2, 2025